Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProGem: Proglumide with Gemcitabine and Nab-Paclitaxel in Metastatic Pancreatic Cancer
NCT05827055Phase 2Active, not recruiting
- Sponsor
- Georgetown University
- Start
- Jan 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Proglumide in pancreatic cancer (PC) (3 arms), sponsored by Georgetown University. Primary endpoint: Safety of oral proglumide therapy at 1200mg daily dose with chemotherapy at 18 months. Started Jan 2024; status: active, not recruiting.
02
Drugs
Proglumide
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05827055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05827055.